Kane Biotech was preparing the annual financial statements and, as part of the year-end procedures, assessed the assets and prepared the following alphabetized schedule based on adjusted values at December 31, 2020: (Do not round intermediate calculations. Round final answers to nearest whole dollar.) Useful Life 7,300 units Date of Purchase May 1/15 Jun. 28/15 Apr. 5/15 Apr. 5/15 Apr. 5/15 Asset Equipment Furniture Land Office building Warehouse Deprec. Method* Units DDB N/A SL SL 8 yrs Residual Value $ 4,310 2,300 N/A 19,700 13,000 Cost $ 43,000 15,000 88,000 83,000 59,500 Accum. Deprec. $ 22,790 12,119 N/A 25,700 15,938 Recoverable Amount $ 7,310 3,250 104,800 55,500 48, 100 N/A 15 yrs 20 yrs *DDB = Double-declining-balance; SL = Straight-line; Units = Units-of-production; N/A = Not applicable Required: 1. Record any impairment losses at December 31, 2020. Assume Kane Biotech has recorded no impairment losses in previous years. 2. Record depreciation for each asset at December 31, 2021. Assume that there was no change in the residual values or useful lives regardless of any impairment losses that might have occurred. The equipment produced 1,950 units during 2021